- Home
- STTK vs MODD Comparison
STTK vs MODD Comparison
Compare STTK & MODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- MODD
- Stock Information
- Founded
- STTK 2016
- MODD 1998
- Country
- STTK United States
- MODD United States
- Employees
- STTK N/A
- MODD N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- MODD Industrial Specialties
- Sector
- STTK Health Care
- MODD Health Care
- Exchange
- STTK Nasdaq
- MODD Nasdaq
- Market Cap
- STTK 36.2M
- MODD 35.5M
- IPO Year
- STTK 2020
- MODD N/A
- Fundamental
- Price
- STTK $0.84
- MODD $0.92
- Analyst Decision
- STTK Hold
- MODD
- Analyst Count
- STTK 4
- MODD 0
- Target Price
- STTK $3.00
- MODD N/A
- AVG Volume (30 Days)
- STTK 305.5K
- MODD 122.6K
- Earning Date
- STTK 05-01-2025
- MODD 02-13-2025
- Dividend Yield
- STTK N/A
- MODD N/A
- EPS Growth
- STTK N/A
- MODD N/A
- EPS
- STTK N/A
- MODD N/A
- Revenue
- STTK $5,721,000.00
- MODD N/A
- Revenue This Year
- STTK N/A
- MODD N/A
- Revenue Next Year
- STTK N/A
- MODD N/A
- P/E Ratio
- STTK N/A
- MODD N/A
- Revenue Growth
- STTK 245.26
- MODD N/A
- 52 Week Low
- STTK $0.69
- MODD $0.68
- 52 Week High
- STTK $11.76
- MODD $2.65
- Technical
- Relative Strength Index (RSI)
- STTK 44.82
- MODD 48.62
- Support Level
- STTK $0.73
- MODD $0.79
- Resistance Level
- STTK $0.90
- MODD $0.95
- Average True Range (ATR)
- STTK 0.15
- MODD 0.10
- MACD
- STTK 0.00
- MODD 0.00
- Stochastic Oscillator
- STTK 19.96
- MODD 55.12
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.